| Lactobacillus rhamnosus GG Activation of Dendritic Cells and Neutrophils Depends on the Dose and Time of Exposure S Cai, M Kandasamy, JN Rahmat, SM Tham, BH Bay, YK Lee, ... Journal of immunology research 2016 (1), 7402760, 2016 | 54 | 2016 |
| Tumor and microenvironment modification during progression of murine orthotopic bladder cancer SM Tham, KH Ng, SH Pook, K Esuvaranathan, R Mahendran Journal of Immunology Research 2011 (1), 865684, 2011 | 35 | 2011 |
| Tryptophan–kynurenine ratio as a biomarker of bladder cancer SH Lee, R Mahendran, SM Tham, TP Thamboo, BJ Chionh, YX Lim, ... BJU international 127 (4), 445-453, 2021 | 26 | 2021 |
| A murine orthotopic bladder tumor model and tumor detection system SM Tham, K Esuvaranathan, R Mahendran JoVE (Journal of Visualized Experiments), e55078, 2017 | 11 | 2017 |
| MP56-19 LONG TERM RESULTS OF A DOUBLE-BLIND RANDOMIZED CONTROLLED TRIAL OF INTERFERON ALPHA-2B AND LOW DOSE BCG IN PATIENTS WITH HIGH RISK NON-MUSCLE-INVASIVE BLADDER CANCER K Esuvaranathan, SM Tham, M Ravuru, R Kamaraj, TP Ng, YH Chan, ... The Journal of Urology 191 (4S), e571-e571, 2014 | 6 | 2014 |
| Gmcsf and Ifnα gene therapy improves the response to BCG immunotherapy in a murine model of bladder cancer SM Tham, R Mahendran, E Chiong, QH Wu, K Esuvaranathan Future Oncology 16 (17), 1179-1188, 2020 | 5 | 2020 |
| Intravesical High Dose BCG Tokyo and Low Dose BCG Tokyo with GMCSF+IFN α Induce Systemic Immunity in a Murine Orthotopic Bladder Cancer Model SM Tham, JN Rahmat, E Chiong, Q Wu, K Esuvaranathan, R Mahendran Biomedicines 9 (12), 1766, 2021 | 2 | 2021 |
| Combination Bacillus Calmette-Guérin and indoleamine 2, 3-dioxygenase 1 inhibitor therapy of murine orthotopic bladder cancer SH Lee, R Mahendran, SM Tham, TP Thamboo, DYQ Kioh, LWT Tang, ... BJU international 126 (5), 554-556, 2020 | 2 | 2020 |
| Long term results of a double-blind randomised controlled trial of interferon alpha-2b and low dose BCG in patients with high risk non-muscle-invasive bladder cancer K Esuvaranathan, SM Tham, M Ravuru, R Kamaraj, TP Ng, YH Chan, ... BJU INTERNATIONAL 113, 1-1, 2014 | 2 | 2014 |
| Gene Therapy in Urology R Mahendran, SM Tham, K Esuvaranathan Gene Therapy Applications, 2011 | 1 | 2011 |
| BCG & interferon alpha: defining its benefits & limitations in high risk non-muscle invasive urothelial carcinoma after long follow-up K Esuvaranathan, SM Tham, QH Wu, L Feng, R Lata International Journal of Urology 17, A52-A53, 2010 | 1 | 2010 |
| Glutathione-S-Transferase Theta 2 (GSTT2) Modulates the Response to Bacillus Calmette–Guérin Immunotherapy in Bladder Cancer Patients JN Rahmat, SM Tham, TL Ong, YK Lim, MV Patwardhan, LRN Mani, ... International Journal of Molecular Sciences 25 (16), 2024 | | 2024 |
| Characterization and prediction of OATP1B activity in prostate cancer patients on abiraterone acetate using endogenous biomarker coproporphyrin I Z Wang, KHY Luk, EJY Cheong, SM Tham, R Periaswami, PC Toh, ... Drug Metabolism and Disposition, 2024 | | 2024 |
| The impact of age on the immune response to BCGurology center M Patwardhan, SM Tham, YK Lim, S Qin, D Ooi, R Periaswami, ... BJU INTERNATIONAL 132, 22-22, 2023 | | 2023 |
| A Novel Clinical Prostate Score (CLIPS) for Minimally Invasive Therapy (MIST) of Prostate WC Tsang, AJY Quek, TYX Law, XWG Pek, SM Tham, WJ Chua, ... European Urology 83, S41-S42, 2023 | | 2023 |
| Intravesical High Dose BCG Tokyo and Low Dose BCG Tokyowith GMCSF+ IFNa Induce Systemic Immunity in a MurineOrthotopic Bladder Cancer Model SM Tham, J Rahmat, E Chiong, QH Wu, K Esuvaranathan, R Mahendran Multidisciplinary Digital Publishing Institute (MDPI), 2021 | | 2021 |
| Can immunologic biomarkers (CD4/CD8/CD25/CD138) predict tumor recurrence and progression in NMIBC? JN Rahmat, KW Tan, TL Ong, SM Tham, CW Tsung, YH Chan, L Raman, ... CLINICAL CANCER RESEARCH 26 (15), 33-34, 2020 | | 2020 |
| Gene expression changes associated with metastasis in mice with bladder cancer. SM Tham, SA Fung, K Esuvaranathan, R Mahendran CLINICAL CANCER RESEARCH 26 (15), 39-40, 2020 | | 2020 |
| Bladder cancer-derived extracellular vesicles and immune activation. SM Tham, K Esuvaranathan, R Mahendran CLINICAL CANCER RESEARCH 26 (15), 36-37, 2020 | | 2020 |
| Abstract A07: A marker to optimize BCG dosing schedules for immunotherapy JN Rahmat, KW Tan, TL Ong, SM Tham, CW Tsung, YH Chan, L Raman, ... Clinical Cancer Research 26 (15_Supplement), A07-A07, 2020 | | 2020 |
